Coeptis Therapeutics Holdings, Inc. announced on January 22, 2025, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), known as the Bid Price Rule. This achievement follows the Nasdaq Hearings Panel's decision of September 17, 2024. The company had previously implemented a 1-for-20 reverse stock split to address this requirement.
Dave Mehalick, Coeptis' Chief Executive Officer, expressed gratitude to the Nasdaq Hearings Panel for approving the company's request. He stated that regaining compliance with Nasdaq's listing standards is an encouraging start to what the company believes will be a transformative year. This ensures the company's continued presence on the Nasdaq Capital Market.
The compliance removes a significant regulatory hurdle for Coeptis. Maintaining a Nasdaq listing is crucial for investor confidence and access to capital markets. This development supports the company's ongoing strategic initiatives and its evolving business model.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.